Improving fecal transplantation precision for enhanced maturation of intestinal function in germ-free mice through microencapsulation and probiotic interventionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers tested whether modifying donor fecal microbiota before fecal microbiota transplantation (FMT) could improve gastrointestinal development in germ-free mice, moving beyond simply picking "super donors".
How was it studied?
Donor stool was pretreated with the probiotic Pediococcus pentosaceus Li05 and then microencapsulated to protect bacterial viability during transit, before transplantation into germ-free mice.
What did they find?
Probiotic treatment temporarily destabilized the donor microbiota, then settled into a more complex bacterial network within 14 days. Encapsulated, Li05-modulated stool improved epithelial development, barrier function, and colonic gene expression, driven mainly by the abundance of Parabacteroides, Parasutterella, Lachnoclostridium, Muribaculum and Desulfovibrio rather than their network interactions. The transplant also shifted host lipid metabolism, particularly bile acids, and Li05 modulation enabled sporulating bacteria (sporobiota) to support epithelial gene expression through elevated Lachnoclostridium.
Why it matters
The findings suggest encapsulation and targeted probiotic conditioning of donor stool, rather than donor selection alone, could make FMT more precise and effective.